SENATE BILL 5507
State of Washington | 67th Legislature | 2022 Regular Session |
BySenators Keiser, Muzzall, Lovick, and C. Wilson
Prefiled 12/07/21.Read first time 01/10/22.Referred to Committee on Health & Long Term Care.
AN ACT Relating to exempting a manufacturer of certain dialysate and dialysis devices used by home dialysis patients or a manufacturer's agent from the pharmacy practices act and legend drug act; and amending RCW
18.64.257 and
69.41.032.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
Sec. 1. RCW
18.64.257 and 2013 c 19 s 20 are each amended to read as follows:
This chapter shall not prevent a medicare-approved dialysis center or facility operating a medicare-approved home dialysis program
, or a manufacturer of commercially available dialysate and dialysis devices used by home dialysis patients, or a manufacturer's agent acting on behalf of such manufacturer, from selling, delivering, possessing, or dispensing directly to its dialysis patients, ((
in case or full shelf lots,)) if prescribed by a physician licensed under chapter
18.57 or
18.71 RCW,
dialysis devices and those legend drugs
, in case or full shelf lots, determined by the commission pursuant to rule.
Sec. 2. RCW
69.41.032 and 2016 c 148 s 12 are each amended to read as follows:
This chapter shall not prevent a medicare-approved dialysis center or facility operating a medicare-approved home dialysis program
, or a manufacturer of commercially available dialysate used by home dialysis patients, or a manufacturer's agent acting on behalf of such manufacturer, from selling, delivering, possessing, or dispensing directly to its dialysis patients, in case or full shelf lots, if prescribed by a physician licensed under chapter
18.57 or
18.71 RCW, those legend drugs determined by the commission pursuant to rule.
--- END ---